Stocks/DMRA

DMRA

Galecto, Inc.
Healthcare·Biotechnology
$24.88
$1.5B market cap
Revenue
$0.0M
Free Cash Flow
$-20.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

2-Year Price History

$25.30-13.1%
$20$22$24$26$28$30volFeb 26Feb 26Mar 26Mar 26Apr 26Apr 26May 26May 26

Quarterly Financials & Projections

Quarterly Waterfall ($ M)
PeriodRevEBITDAOpInNIOCFFCFCapExCashDebtSharesROICIntCovEV/EBITDA
Act2026-Q10.0-30.7-30.8-27.8-20.6-20.6-0.0532.91.31.3-35.4%----
Act2025-Q40.0-201.7-201.7-200.70.60.6-0.0257.60.11.3<-999%----

Valuation & Metrics

Market Stats

Price$24.88
Market Cap$1.5B
Enterprise Value$1000M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-1.3%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD

TTM Financial Snapshot

Revenue$0.0M
Net Income$-228.5M
Free Cash Flow$-20.0M

Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-533.7%
WC Change % Rev0.0%
Interest Coverage--

Forward Outlook & Risk

Short Interest

Short % of Float--
Short Shares1.2M
Days to Cover5.5
Change (vs Prior)+6.7%
Need at least 2 settlement dates for chart

Employees

Headcount7
Revenue / Employee$0
Gross Profit / Employee$-9,714

Institutional Ownership

Headline & net flow

NEUTRAL
Net flow · still filing
No float data — flow unavailable.

Ownership composition

Active
95.0%(+95.0% YoY)
54 filers
hedge / family / endowment
Retail funds
Fidelity, Schwab, 401(k)
Passive
1.7%(+1.7% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
3 filers
Citadel, Susquehanna
Insiders
Form 4 — latest per insider
0%25%50%75%100%2024-092025-032025-092026-03
ActiveRetail fundsPassiveMarket makersRetail direct

Top holders

Fund$ valueCost basisΔ QoQΔ YoYα lifeFund AUM
FMR LLC$234M$25.90+$228M+$234M$1.89T
Fairmount Funds Management LLC$226M$25.90+$226M+$226M$1.38B
Avoro Capital Advisors LLC$98.0M$25.90+$98.0M+$98.0M$10.15B
VR Adviser, LLC$93.3M$25.90+$93.3M+$93.3M$2.68B
FCPM III SERVICES B.V.$63.2M$25.90+$63.2M+$63.2M$722M
RA CAPITAL MANAGEMENT, L.P.$62.1M$25.90+$62.1M+$62.1M$9.44B
JANUS HENDERSON GROUP PLC$61.4M$25.90+$61.1M+$61.4M$209.29B
VIKING GLOBAL INVESTORS LP$59.9M$25.90+$59.9M+$59.9M$35.75B
Bellevue Group AG$59.5M$25.90+$59.5M+$59.5M$4.20B
Remedium Capital Partners, LLC$53.0M$25.90+$49.9M+$53.0M$281M
Commodore Capital LP$50.2M$25.90+$50.2M+$50.2M$1.73B
Cormorant Asset Management, LLC$39.5M$25.90+$39.5M+$39.5M$1.95B
BALYASNY ASSET MANAGEMENT LLC$37.5M$25.90+$37.5M+$37.5M$48.01B
a16z Capital Management, L.L.C.$32.0M$25.90+$32.0M+$32.0M$1.29B
PERCEPTIVE ADVISORS LLC$31.7M$25.90+$31.7M+$31.7M$5.05B
Point72 Asset Management, L.P.$30.9M$25.90+$28.1M+$30.9M$54.88B
WELLINGTON MANAGEMENT GROUP LLP$27.4M$25.90+$27.4M+$27.4M$533.98B
Siren, L.L.C.$23.3M$25.90+$23.3M+$23.3M$3.61B
BRAIDWELL LP$23.2M$25.90+$23.2M+$23.2M$2.63B
Vestal Point Capital, LP$15.5M$25.90+$15.5M+$15.5M$3.58B
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.

Trading behavior

Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+2.23%
avg per quarter
Holders (ex-self)
excl. this stock
Buyers (this Q)
+2.20%
62 buyers · $1.43B in
Sellers (this Q)
+0.00%
1 sellers · $-0.00B out
alpha coverage: 99% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-2.9%
how holders react when this stock falls
On quiet Qs
-3.6%
−10% to +10% baseline
On rallies (+10%+)
-4.6%
how they react when this stock rises
Holders' portfolio flow this Q
-4.2%
outflows — trims may be forced
Sellers' portfolio flow this Q
+9.8%
Sellers grew AUM elsewhere — opinionated cut of this stock.

Top Holders Over Time

5-year share-count history (top 10 holders by peak, incl. exited) + price

09.8M19.5M29.3M39.0M$26$26$26$27$272025-122026-03
hover the chart for per-quarter detailprice (right axis)
FMR LLC9.0MFairmount Funds Management LLC8.7MAvoro Capital Advisors LLC3.8MVR Adviser, LLC3.6MFCPM III SERVICES B.V.2.4MRA CAPITAL MANAGEMENT, L.P.2.4MJANUS HENDERSON GROUP PLC2.4MVIKING GLOBAL INVESTORS LP2.3MBellevue Group AG2.3MRemedium Capital Partners, LLC2.0M

Related Stocks

Investors who own this also own

Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.

TickerNameCo-holdersScore
JBIOJade Biosciences, Inc.3236.00×
SYRESpyre Therapeutics, Inc.4166.59×
ERASErasca, Inc.4157.33×
ORKAOruka Therapeutics, Inc.4157.33×
ELVNEnliven Therapeutics, Inc.3124.94×
PHVSPharvaris N.V.3118.00×
DNTHDianthus Therapeutics, Inc.381.69×
COGTCogent Biosciences, Inc.364.36×

Analyst Coverage

Analyst Coverage
Price Targets
Last Quarter (1 analysts)$40.006080.0%
Last Year (1 analysts)$40.006080.0%
Current Price$24.88
Analyst Ratings
1
Buy: 1Consensus: Buy

Corporate

Order Flow (FINRA, ~3w lag)

21.9%retail
27.2%dark
week of 2026-04-13
10%20%30%40%26-0326-0326-0326-0426-04retail (non-ATS)dark (ATS)
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.